Happy news: another research paper of our center has been successfully accepted for publication on Advanced Materials

Our new research paper titled “ROS Responsive Polymeric siRNA Nanomedicine Stabilized by Triple-Interactions for the Robust Glioblastoma Combinational RNAi Therapy” was recently accepted for publication on Advanced Materials (doi: 10.1002/adma.201903277). This paper reports on the use of siRNA nanomedicine with triple acting (charge, hydrogen bond and hydrophobic) stability for the treatment of glioblastoma. Compared with the traditional siRNA nanomedicines that rely only on the charge, the three kinds of charge, hydrogen bond and hydrophobic effect between the polymer and the siRNA designed in this study significantly enhanced the stability of the siRNA nanomedicines and extended blood circulation time. In addition, the nanomedicine also has reactive oxygen species (ROS) response function, which can accelerate siRNA release and exert gene silencing effect in tumor cells. siRNA nanomedicine modified with angiopep-2 can effectively cross the blood-brain barrier and target glioblastoma cells, improving the treatment efficiency. In vivo, siRNA nanomedicines loaded with VEGFR-2 (vascular endothelial growth factor receptor-2) siRNA and PLK1 (polo-like kinase 1) siRNA have synergistic therapeutic effects, inhibiting the growth of glioblastoma and extending the life cycle of mice. The polymer carrier with multiple properties (stable, responsive and targeted) designed in this study lays a good foundation for the delivery of gene drugs in vivo.

Advanced Materials is an international top peer-reviewed journal with a current IF of 25.809.

Dr. Zheng and P.h.D candidate Yuanyuan Liu are the co-first authors. Prof. Shi is the corresponding author. This work was supported by National Natural Science Foundation of China, the National Key Technologies R&D Program of China, the Program of China’s 1000-Talents Plan and the Key Research Program in Colleges and Universities of Henan Province.